BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, Shimada H. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response. Int J Cancer 2006;119:406-13. [DOI: 10.1002/ijc.21843] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Teimoori-toolabi L, Hashemi S, Azadmanesh K, Eghbalpour F, Safavifar F, Khorramizadeh MR. Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line. Anti-Cancer Drugs 2015;26:187-96. [DOI: 10.1097/cad.0000000000000175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer. 2010;9:98. [PMID: 20433755 DOI: 10.1186/1476-4598-9-98] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
3 Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP, Siewert JR. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008;6:53-61. [PMID: 18166477 DOI: 10.1016/j.cgh.2007.10.022] [Cited by in Crossref: 92] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
4 Ballhausen A, Przybilla MJ, Jendrusch M, Haupt S, Pfaffendorf E, Seidler F, Witt J, Hernandez Sanchez A, Urban K, Draxlbauer M, Krausert S, Ahadova A, Kalteis MS, Pfuderer PL, Heid D, Stichel D, Gebert J, Bonsack M, Schott S, Bläker H, Seppälä T, Mecklin JP, Ten Broeke S, Nielsen M, Heuveline V, Krzykalla J, Benner A, Riemer AB, von Knebel Doeberitz M, Kloor M. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nat Commun 2020;11:4740. [PMID: 32958755 DOI: 10.1038/s41467-020-18514-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
5 Lin AY, Chua MS, Choi YL, Yeh W, Kim YH, Azzi R, Adams GA, Sainani K, van de Rijn M, So SK. Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One. 2011;6:e16636. [PMID: 21383983 DOI: 10.1371/journal.pone.0016636] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
6 Guan X, Liao Z, Ma H, Qian J, Liu Z, Yuan X, Gomez D, Komaki R, Wang LE, Wei Q. TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 2011;11:447. [PMID: 21995493 DOI: 10.1186/1471-2407-11-447] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
7 Babic A, Shah SM, Song M, Wu K, Meyerhardt JA, Ogino S, Yuan C, Giovannucci EL, Chan AT, Stampfer MJ, Fuchs CS, Ng K. Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. Br J Cancer 2016;114:995-1002. [PMID: 27031855 DOI: 10.1038/bjc.2016.85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
8 Li X, Li J, Jiang G, Bu L, Yang F, Liu J, Wang J. Influence on the behavior of lung cancer H1299 cells by silencing SLC35F2 expression. Cancer Cell Int 2013;13:73. [PMID: 23879892 DOI: 10.1186/1475-2867-13-73] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Griffith M, Mwenifumbo JC, Cheung PY, Paul JE, Pugh TJ, Tang MJ, Chittaranjan S, Morin RD, Asano JK, Ally AA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013;13:148-158. [PMID: 22249354 DOI: 10.1038/tpj.2011.65] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
10 Hao G, Ding Y, Wen H, Li X, Zhang W, Su H, Liu D, Xie N. Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Biochemical and Biophysical Research Communications 2017;488:501-8. [DOI: 10.1016/j.bbrc.2017.05.075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
11 McHugh SM, O'Donnell J, Gillen P. Genomic and oncoproteomic advances in detection and treatment of colorectal cancer. World J Surg Oncol 2009;7:36. [PMID: 19338662 DOI: 10.1186/1477-7819-7-36] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
12 Ma L, Chen S, Mao X, Lu Y, Zhang X, Lao X, Qin X, Li S. The association between TNFR gene polymorphisms and the risk of Hepatitis B Virus-Related Liver Diseases in Chinese population. Sci Rep 2018;8:9240. [PMID: 29915336 DOI: 10.1038/s41598-018-27623-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chung H, Chaudhry J, Lopez CG, Carethers JM. Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner. Cancer Biol Ther 2010;10:1147-56. [PMID: 20930505 DOI: 10.4161/cbt.10.11.13447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
14 Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010;16:2999-3010. [PMID: 20404007 DOI: 10.1158/1078-0432.CCR-09-3233] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
15 Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas. 2016;45:425-433. [PMID: 26495780 DOI: 10.1097/mpa.0000000000000501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
16 Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008;81:275-300. [PMID: 18259091 DOI: 10.1159/000115967] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 8.0] [Reference Citation Analysis]
17 Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Nakatani Y, Fujisawa T, Yoshino I. Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, Thymidine Phosphorylase, Orotate Phosphoribosyltransferase mRNA Expression in Lung Cancer Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration – A Pilot Study. Clinical Lung Cancer 2011;12:293-7. [DOI: 10.1016/j.cllc.2011.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Kai K, Kitajima Y, Hiraki M, Satoh S, Tanaka M, Nakafusa Y, Tokunaga O, Miyazaki K. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Cancer Lett 2007;258:45-54. [PMID: 17892912 DOI: 10.1016/j.canlet.2007.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
19 Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol 2007;8:339-51. [PMID: 18193357 DOI: 10.1007/s11864-007-0045-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
20 Li KC, Girardi E, Kartnig F, Grosche S, Pemovska T, Bigenzahn JW, Goldmann U, Sedlyarov V, Bensimon A, Schick S, Lin JG, Gürtl B, Reil D, Klavins K, Kubicek S, Sdelci S, Superti-Furga G. Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states. Nat Metab 2021;3:651-64. [PMID: 33972798 DOI: 10.1038/s42255-021-00386-8] [Reference Citation Analysis]
21 Yang C, Yang S, Wood KB, Hornicek FJ, Schwab JH, Fondren G, Mankin H, Duan Z. Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression. Apoptosis 2009;14:124-33. [PMID: 19052873 DOI: 10.1007/s10495-008-0282-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
22 Ulukaya E, Karakas D, Dimas K. Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients. Medicina (Kaunas) 2021;57:636. [PMID: 34205407 DOI: 10.3390/medicina57060636] [Reference Citation Analysis]
23 Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008;21 Suppl 2:S23-S30. [PMID: 18437170 DOI: 10.1038/modpathol.2008.14] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
24 Allen WL, Jithesh PV, Oliver GR, Proutski I, Longley DB, Lenz HJ, Proutski V, Harkin P, Johnston PG. The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. BMC Cancer 2010;10:687. [PMID: 21172019 DOI: 10.1186/1471-2407-10-687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clin Cancer Res 2011;17:4474-83. [PMID: 21555373 DOI: 10.1158/1078-0432.CCR-10-2370] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
26 Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010;29:100. [PMID: 20646319 DOI: 10.1186/1756-9966-29-100] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
27 Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One 2012;7:e43236. [PMID: 22905237 DOI: 10.1371/journal.pone.0043236] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ackland SP, Clarke SJ, Beale P, Peters GJ. Thymidylate synthase inhibitors. Update on Cancer Therapeutics 2006;1:403-27. [DOI: 10.1016/j.uct.2006.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
29 Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Nakayama G, Ohashi N, Koike M, Yamamura Y, Nakao A. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 2007;252:307-313. [PMID: 17303323 DOI: 10.1016/j.canlet.2007.01.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
30 Tani A, Saegusa Y, Ogawa K, Tomiyasu H, Takeuchi Y, Harada K, Kobayashi T, Setoguchi A, Nakamichi J, Mizuno T, Irie M, Tokita M, Fujita K, Suenaga M, Motegi T, Ohmi A, Goto-Koshino Y, Ohno K, Tsujimoto H. Construction and validation of a scoring system to predict resistance to chemotherapeutic drugs using gene expression profiles in canine lymphoma. Res Vet Sci 2021;137:208-16. [PMID: 34020336 DOI: 10.1016/j.rvsc.2021.05.007] [Reference Citation Analysis]
31 Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006;95:607-15. [PMID: 16880781 DOI: 10.1038/sj.bjc.6603297] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
32 Hara-Yamamura H, Nakashima K, Fukushima T, Okabe S. Transcriptomic response of HepG2 cells exposed to three common anti-inflammatory drugs: Ketoprofen, mefenamic acid, and diclofenac in domestic wastewater effluents. Chemosphere 2021;286:131715. [PMID: 34388874 DOI: 10.1016/j.chemosphere.2021.131715] [Reference Citation Analysis]
33 Cui J, Zhang N, Liu Y, Zhang L, Gao C, Liu S. Microarray gene expression profiling provides insights into functions of TIPE2 in HBV-related apoptosis. Mol Immunol 2021;131:137-43. [PMID: 33419563 DOI: 10.1016/j.molimm.2020.12.031] [Reference Citation Analysis]
34 Ariyan CE, Salem RR. Evolution in the treatment of metastatic colorectal carcinoma of the liver. World J Gastroenterol 2006;12:3253-8. [PMID: 16718848 DOI: 10.3748/wjg.v12.i20.3253] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
35 Zhang Y, Gao J, Wang X, Deng S, Ye H, Guan W, Wu M, Zhu S, Yu Y, Han W. CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity. Cancer Biol Ther. 2015;16:1775-1783. [PMID: 26479470 DOI: 10.1080/15384047.2015.1095404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
36 Unger FT, Witte I, David KA. Prediction of individual response to anticancer therapy: historical and future perspectives. Cell Mol Life Sci 2015;72:729-57. [PMID: 25387856 DOI: 10.1007/s00018-014-1772-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
37 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
38 Coyle VM, Johnston PG. Genomic markers for decision making: what is preventing us from using markers? Nat Rev Clin Oncol 2010;7:90-7. [DOI: 10.1038/nrclinonc.2009.214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
39 Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 2006;6:288-96. [PMID: 17241513 DOI: 10.3816/CCC.2006.n.047] [Cited by in Crossref: 50] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
40 Nobili S, Napoli C, Landini I, Morganti M, Cianchi F, Valanzano R, Tonelli F, Cortesini C, Mazzei T, Mini E. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int J Cancer 2011;128:1935-45. [DOI: 10.1002/ijc.25514] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
41 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20:9775-9827. [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]